BioMarin taps AI upstart Deep Genomics for discovery pact; Praxis says it has a path to lifting clinical hold
Years after double FDA/EMA rejections left BioMarin’s oligonucleotide for Duchenne muscular dystrophy languishing on the shelf, the company is going back to the drawing board for new oligonucleotide drug candidates — with a healthy dose of artificial intelligence.
Its partner of choice is Deep Genomics, a Toronto-based shop led by star researcher Brendan Frey. Paid an undisclosed upfront, their mandate is to identify and validate new target mechanisms in rare diseases as well as lead candidates. BioMarin will then take over the preclinical work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.